Danske Bank A S Has $66,000 Holdings in Exelixis, Inc. $EXEL

Danske Bank A S cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 99.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,500 shares of the biotechnology company’s stock after selling 234,545 shares during the quarter. Danske Bank A S’s holdings in Exelixis were worth $66,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of EXEL. Richardson Financial Services Inc. lifted its holdings in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in shares of Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after buying an additional 500 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Exelixis during the third quarter worth approximately $28,000. Activest Wealth Management acquired a new position in shares of Exelixis during the fourth quarter worth approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q1 beat and large buyback — Exelixis reported stronger-than-expected Q1 EPS and net income and launched a new $750M share repurchase program, which management says will drive EPS accretion and supports shareholder returns. Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program
• Positive Sentiment: Expanded buyback & PDUFA timing for zanzalintinib — Company disclosed the $750M authorization and outlined a December PDUFA timeline for a colorectal cancer filing for zanzalintinib (ZANZA), adding optionality to future revenue. Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback
• Positive Sentiment: Analyst bullishness and price-target increases — Multiple firms raised targets (HC Wainwright to $56, TD Cowen to $55 and others raising to ~$50–$56), signaling confidence in cabozantinib momentum and buyback-driven EPS. Benzinga: HC Wainwright price target raise
• Neutral Sentiment: Investor events scheduled — Management will host fireside chats at major investor conferences in May (BofA, RBC, Stifel), providing additional opportunities for guidance and Q&A that could influence near-term sentiment. Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
• Neutral Sentiment: Mixed analyst posture — Morgan Stanley nudged its target to $50 but kept an Equal-Weight/Hold stance, and Stifel raised a target modestly; these show cautious optimism but not unanimous buy conviction. Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00 at Morgan Stanley
• Negative Sentiment: Zanzalintinib/regulatory and pipeline risks flagged — Management and analysts flagged risks around ZANZA development and regulatory timelines on the earnings call, which could add binary risk to forward valuation. Exelixis Earnings Call Highlights Growth And ZANZA Risks
• Negative Sentiment: Sales mix and revenue nuance — Some coverage notes cabozantinib (Cabometyx) growth is solid but trailing certain estimates and revenue miss signals modest near-term commercial headwinds that may temper multiple expansion. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
• Negative Sentiment: Some cautious analyst views remain — Wells Fargo’s equal-weight target implies downside vs. current levels, reflecting divergent street views that can amplify volatility. Benzinga: Wells Fargo price target note

Insider Transactions at Exelixis

In other Exelixis news, SVP Brenda Hefti sold 18,669 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $821,622.69. Following the sale, the senior vice president directly owned 96,512 shares in the company, valued at $4,247,493.12. This represents a 16.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the sale, the executive vice president owned 381,908 shares in the company, valued at $16,620,636.16. This trade represents a 15.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 362,849 shares of company stock valued at $15,917,463. 2.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of research analyst reports. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Truist Financial upgraded Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. Wells Fargo & Company boosted their price objective on Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and an average price target of $47.83.

Exelixis Trading Down 5.1%

EXEL opened at $46.21 on Friday. The stock has a market cap of $11.61 billion, a PE ratio of 15.35, a P/E/G ratio of 1.09 and a beta of 0.38. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $49.62. The stock’s 50 day simple moving average is $43.44 and its 200-day simple moving average is $42.97.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. During the same period in the prior year, the business posted $0.55 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. Equities analysts forecast that Exelixis, Inc. will post 3.07 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.